About 1 in 18 healthy adults over 70 have a detectable blood cell mutation called CHIP at a high level (10% or more), but this does not appear to raise their risk of heart attacks or strokes.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A meta-analysis could confirm whether the 5–6% prevalence of high-level CHIP in older adults is consistent across diverse populations and whether it consistently lacks association with CVD events.
A systematic review and meta-analysis of 15+ population-based cohorts with deep sequencing for CHIP (VAF ≥10%) in adults aged 65+, reporting incidence of MACE over 5+ years, adjusting for age, sex, smoking, and diabetes.
An RCT could test whether reducing CHIP burden (e.g., via anti-inflammatory agents) reduces CVD events, but this would not validate the baseline prevalence.
A double-blind RCT of 1,500 adults aged 70+ with CHIP (VAF ≥10%) randomized to an agent targeting clonal expansion (e.g., canakinumab) vs. placebo for 4 years, with MACE as primary endpoint. Not relevant for prevalence estimation.
A prospective cohort could validate the 5.6% prevalence and confirm the absence of CVD risk over time in a different population.
A prospective cohort of 12,000 adults aged 70+ from multiple countries, with baseline CHIP sequencing (VAF ≥10%) and annual follow-up for 7 years for MACE events, using standardized adjudication and adjustment for cardiovascular risk factors.
A cross-sectional study could estimate the prevalence of high-level CHIP in a single population at one time point.
A single-timepoint survey of 5,000 community-dwelling adults aged 70+ without CVD, using targeted sequencing to detect CHIP at VAF ≥10%, with demographic and clinical data collected concurrently.
Case reports could describe rare individuals with very high VAF and CVD, but cannot inform population-level risk.
A series of 10–20 case reports of individuals aged 70+ with VAF ≥20% and incident MACE, documenting clinical course and CHIP mutation profile.